
Sign up to save your podcasts
Or


Tell us a little bit about your background and about yourself.
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?
So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?
What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
Resources
Plasma Cell Proliferative Disorder [A Test in Focus]
Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)
Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow (Mayo test ID: MSMRT)
Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)
Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244
By Mayo Clinic Laboratories5
2121 ratings
Tell us a little bit about your background and about yourself.
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?
So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?
What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
Resources
Plasma Cell Proliferative Disorder [A Test in Focus]
Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)
Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow (Mayo test ID: MSMRT)
Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)
Mellors et al.: Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances. 2020;4(10): 2236-2244

90,967 Listeners

43,816 Listeners

32,003 Listeners

38,498 Listeners

43,582 Listeners

291 Listeners

16,908 Listeners

6,095 Listeners

3,649 Listeners

57,840 Listeners

48 Listeners

29,246 Listeners

1,654 Listeners

13,445 Listeners

9 Listeners